详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

EZH2 in hepatocellular carcinoma: progression, immunity, and potential targeting therapies

50| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

单位： [1]Hepatic Surgery Center,Institute of Hubei Key Laboratory of Hepato- Pancreato-Biliary Diseases,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [2]Department of Hepatobiliary Surgery,Shanxi Tongji Hospital,Tongji Medical College,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Shanxi Medical University,Huazhong University of Science and Technology,Taiyuan 030032,China [3]Key Laboratory of Hepatobiliary and Pancreatic Diseases of Shanxi Province (Preparatory),Shanxi Tongji Hospital,Tongji Medical College,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Shanxi Medical University,Huazhong University of Science and Technology,Taiyuan 030032,China

出处：

DOI：

ISSN：

摘要：

Hepatocellular carcinoma (HCC) is the leading cause of cancer-related death. The accumulation of genetic and epigenetic changes is closely related to the occurrence and development of HCC. Enhancer of zeste homolog 2 (EZH2, a histone methyltransferase) is suggested to be one of the principal factors that mediates oncogenesis by acting as a driver of epigenetic alternation. Recent studies show that EZH2 is widely involved in proliferation and metastasis of HCC cells. In this review, the functions of EZH2 in HCC progression, the role of EZH2 in tumor immunity and the application of EZH2-related inhibitors in HCC therapy are summarized.© 2023. The Author(s).

基金：

语种：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2022]版：

大类 | 2 区医学

小类 | 2 区血液学 2 区肿瘤学

最新[2025]版：

大类 | 2 区医学

小类 | 2 区血液学 2 区肿瘤学

JCR分区：

出版当年[2021]版：

Q1 HEMATOLOGY Q1 ONCOLOGY

最新[2023]版：

Q1 HEMATOLOGY Q1 ONCOLOGY

影响因子： 9.4 最新[2023版] 8.3 最新五年平均 8.593 出版当年[2021版] 5.914 出版当年五年平均 5.133 出版前一年[2020版] 11.4 出版后一年[2022版]

第一作者：

第一作者单位： [1]Hepatic Surgery Center,Institute of Hubei Key Laboratory of Hepato- Pancreato-Biliary Diseases,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China

共同第一作者：

通讯作者：

通讯机构： [1]Hepatic Surgery Center,Institute of Hubei Key Laboratory of Hepato- Pancreato-Biliary Diseases,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China [2]Department of Hepatobiliary Surgery,Shanxi Tongji Hospital,Tongji Medical College,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Shanxi Medical University,Huazhong University of Science and Technology,Taiyuan 030032,China [3]Key Laboratory of Hepatobiliary and Pancreatic Diseases of Shanxi Province (Preparatory),Shanxi Tongji Hospital,Tongji Medical College,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Shanxi Medical University,Huazhong University of Science and Technology,Taiyuan 030032,China

推荐引用方式(GB/T 7714)：

APA：

MLA：